Kirsty

Insulin Aspart, the active ingredient in Kirsty, is a rapid‑acting insulin analog presented as a solution for subcutaneous use. It is used to lower blood glucose in people with diabetes mellitus, including both type 1 and type 2 disease. GNH USA supplies Kirsty as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kirsty (Insulin Aspart) is a rapid‑acting insulin analog that acts on the glucose regulation pathway in diabetes mellitus.

Type 1 diabetes mellitus: provides mealtime insulin coverage to control post‑prandial blood glucose spikes. Type 2 diabetes mellitus: supplements oral agents or basal insulin to achieve target glycaemic control after meals.

Insulin Aspart may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes, especially if meals are missed or delayed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilization.

Serious or Rare Side Effects: - Severe hypoglycaemia: neurological impairment requiring immediate assistance. - Allergic reactions: rash, urticaria, or anaphylaxis in susceptible individuals. - Lipodystrophy: abnormal fat accumulation or loss at injection sites. - Hypokalemia: low potassium levels, particularly with high insulin doses.

When using Kirsty, consider the following safety measures.

Monitor blood glucose regularly: adjust dose based on readings and meal timing. Avoid dosing before intense exercise: risk of hypoglycaemia increases. Use with caution in renal impairment: altered insulin clearance may require dose modification. Pregnancy considerations: discuss potential risks and benefits with a healthcare provider. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart can interact with several medications, affecting glycaemic control.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection. - MAO inhibitors: can cause unpredictable blood glucose fluctuations. - Glucagon antagonists: may blunt counter‑regulatory response to low glucose.

Moderate Interactions (Monitor Closely): - Alcohol: enhances insulin’s glucose‑lowering effect, increasing hypoglycaemia risk. - Thiazolidinediones: additive glucose‑lowering effect may require dose adjustment. - Other insulin preparations: concurrent use can lead to overdose and severe hypoglycaemia.